Oscotec Inc.
  • Company
    • About us
    • History
    • Leadership
    • Location
  • SCIENCE
    • PIPELINE
    • ACART
    • PUBLICATION
  • INVESTORS
    • Notice
    • Financial Info
    • IR Material
    • Press Releases
    • Public Disclosures
  • SUSTAINABILITY
    • Governance
      • Code of Ethics
      • Board
      • Committee
      • Audit
      • Articles of Inc.
    • ESG Portal
  • Contact
    • Contact us
    • Report a Concern
    • Privacy Policy
    • Careers
a
  • English
M
  • English

COMPANY

  • About us
  • History
  • Leadership
  • Location

SCIENCE

  • PIPELINE
  • ACART
  • Publication

INVESTORS

  • Notice
  • Financial Info
  • IR Material
  • Press Releases
  • Public Disclosures

Sustainability

  • Governance
    • Code of Ethics
    • Board
    • Committee
    • Audit
    • Articles of Inc.
  • ESG Portal

CONTACT

  • Contact us
  • Report a Concern
  • Privacy Policy
  • Careers
  • English

FDA

Read our latest update

Oscotec Inc. Gains FDA Orphan Drug Designation for Promising ITP Treatment Cevidoplenib

Mar 22, 2024

Privacy Policy |  Company   |   SCIENCE   |    INVESTORS  |   SUSTAINABILITY  |  Contact
Address: 9F, Bldg. A, Korea Bio-Park, 700 Daewangpangyo-ro,
Bundang-gu, Seongnam-si, Gyeonggi-do 13488 Republic of Korea
CEO: Taeyoung Yoon, Sanghyun Lee
Business Registration No.: 312-81-32175











Contact
GENOSCO
Copyright © OSCOTEC Inc. 2026. All Rights Reserved.